JP2020516673A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516673A5
JP2020516673A5 JP2019556314A JP2019556314A JP2020516673A5 JP 2020516673 A5 JP2020516673 A5 JP 2020516673A5 JP 2019556314 A JP2019556314 A JP 2019556314A JP 2019556314 A JP2019556314 A JP 2019556314A JP 2020516673 A5 JP2020516673 A5 JP 2020516673A5
Authority
JP
Japan
Prior art keywords
based hbv
protein
nucleic acid
hbv vaccine
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019556314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516673A (ja
JP7688480B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/028116 external-priority patent/WO2018195165A1/en
Publication of JP2020516673A publication Critical patent/JP2020516673A/ja
Publication of JP2020516673A5 publication Critical patent/JP2020516673A5/ja
Priority to JP2023088820A priority Critical patent/JP2023123449A/ja
Application granted granted Critical
Publication of JP7688480B2 publication Critical patent/JP7688480B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019556314A 2017-04-18 2018-04-18 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法 Active JP7688480B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023088820A JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762486618P 2017-04-18 2017-04-18
US62/486,618 2017-04-18
US201762553358P 2017-09-01 2017-09-01
US62/553,358 2017-09-01
US201862646978P 2018-03-23 2018-03-23
US62/646,978 2018-03-23
PCT/US2018/028116 WO2018195165A1 (en) 2017-04-18 2018-04-18 Methods for the treatment of subjects having a hepatitis b virus (hbv) infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023088820A Division JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Publications (3)

Publication Number Publication Date
JP2020516673A JP2020516673A (ja) 2020-06-11
JP2020516673A5 true JP2020516673A5 (enExample) 2021-05-27
JP7688480B2 JP7688480B2 (ja) 2025-06-04

Family

ID=71013269

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556314A Active JP7688480B2 (ja) 2017-04-18 2018-04-18 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法
JP2023088820A Pending JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023088820A Pending JP2023123449A (ja) 2017-04-18 2023-05-30 Ｂ型肝炎ウイルス（ｈｂｖ）感染を有する対象を処置する方法

Country Status (1)

Country Link
JP (2) JP7688480B2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114507663B (zh) * 2020-11-16 2026-07-17 浙江柏拉阿图医药科技有限公司 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用
US20250099577A1 (en) * 2022-01-25 2025-03-27 Kawasaki Institute Of Industrial Promotion Rna-containing composition for transdermal administration, and method for administering said composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI769565B (zh) 2014-11-10 2022-07-01 美商阿尼拉製藥公司 Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
EP3402888B1 (en) 2016-01-12 2020-08-26 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating hbv

Similar Documents

Publication Publication Date Title
US20170211068A1 (en) Immunostimulation by chemically modified rna
JP5087758B2 (ja) アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
EP2019857B1 (en) Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
ES2340499T3 (es) Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
US6919319B2 (en) Immuno-modulating effects of chemokines in DNA vaccination
KR20050048539A (ko) ＣｐＧ 제제 및 관련된 방법
KR20110102424A (ko) 면역자극성 올리고뉴클레오타이드
US20250171507A1 (en) Cpg amphiphiles and uses thereof
EA007232B1 (ru) Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
BRPI0920240B1 (pt) composição adjuvante
TW201408309A (zh) 用於治療ｂ型肝炎及ｄ型肝炎感染之方法
RU2008102930A (ru) Способы введения вакцин, новые калицивирусы кошки и варианты лечения для иммунизации животных против парвовируса кошки и вируса герпеса кошки
KR100773390B1 (ko) 단순 포진 바이러스 백신 키트
CZ20014377A3 (cs) Koňský GM-CSF
CN114423430A (zh) 使用核心蛋白别构调节剂治疗hbv感染的方法
JP2004533431A (ja) アジュバントとしてｉ型ｉｆｎを含むワクチン及びそれと関連する方法
Weeratna et al. Optimization strategies for DNA vaccines
US7384641B2 (en) Immuno-modulating effects of chemokines in DNA vaccination
EP4438047A1 (en) Biological response modifiers for the treatment of subjects with underperforming immune systems and compositions thereof
JP7855515B2 (ja) Ｂ型肝炎およびｄ型肝炎を治療および予防するための組成物および方法
RU2823677C2 (ru) Cpg амфифилы и их применения
WO2022034555A1 (en) Polynucleotide constructs and uses thereof
Myers et al. Tumor immunity and prolonged survival following combined adenovirus-HSP72 and CEA-plasmid vaccination
Madaan Heplisav V
HK40043266A (en) Cpg amphiphiles and uses thereof